...
首页> 外文期刊>Medical Physics >Report of the Task Group 186 on model-based dose calculation methods in brachytherapy beyond the TG-43 formalism: Current status and recommendations for clinical implementation
【24h】

Report of the Task Group 186 on model-based dose calculation methods in brachytherapy beyond the TG-43 formalism: Current status and recommendations for clinical implementation

机译:TG-43形式之外的近距离放射治疗中基于模型的剂量计算方法的第186号任务组的报告:现状和临床实施建议

获取原文
获取原文并翻译 | 示例
           

摘要

The charge of Task Group 186 (TG-186) is to provide guidance for early adopters of model-based dose calculation algorithms (MBDCAs) for brachytherapy (BT) dose calculations to ensure practice uniformity. Contrary to external beam radiotherapy, heterogeneity correction algorithms have only recently been made available to the BT community. Yet, BT dose calculation accuracy is highly dependent on scatter conditions and photoelectric effect cross-sections relative to water. In specific situations, differences between the current water-based BT dose calculation formalism (TG-43) and MBDCAs can lead to differences in calculated doses exceeding a factor of 10. MBDCAs raise three major issues that are not addressed by current guidance documents: (1) MBDCA calculated doses are sensitive to the dose specification medium, resulting in energy-dependent differences between dose calculated to water in a homogeneous water geometry (TG-43), dose calculated to the local medium in the heterogeneous medium, and the intermediate scenario of dose calculated to a small volume of water in the heterogeneous medium. (2) MBDCA doses are sensitive to voxel-by-voxel interaction cross sections. Neither conventional single-energy CT nor ICRUICRP tissue composition compilations provide useful guidance for the task of assigning interaction cross sections to each voxel. (3) Since each patient-source-applicator combination is unique, having reference data for each possible combination to benchmark MBDCAs is an impractical strategy. Hence, a new commissioning process is required. TG-186 addresses in detail the above issues through the literature review and provides explicit recommendations based on the current state of knowledge. TG-43-based dose prescription and dose calculation remain in effect, with MBDCA dose reporting performed in parallel when available. In using MBDCAs, it is recommended that the radiation transport should be performed in the heterogeneous medium and, at minimum, the dose to the local medium be reported along with the TG-43 calculated doses. Assignments of voxel-by-voxel cross sections represent a particular challenge. Electron density information is readily extracted from CT imaging, but cannot be used to distinguish between different materials having the same density. Therefore, a recommendation is made to use a number of standardized materials to maintain uniformity across institutions. Sensitivity analysis shows that this recommendation offers increased accuracy over TG-43. MBDCA commissioning will share commonalities with current TG-43-based systems, but in addition there will be algorithm-specific tasks. Two levels of commissioning are recommended: reproducing TG-43 dose parameters and testing the advanced capabilities of MBDCAs. For validation of heterogeneity and scatter conditions, MBDCAs should mimic the 3D dose distributions from reference virtual geometries. Potential changes in BT dose prescriptions and MBDCA limitations are discussed. When data required for full MBDCA implementation are insufficient, interim recommendations are made and potential areas of research are identified. Application of TG-186 guidance should retain practice uniformity in transitioning from the TG-43 to the MBDCA approach.
机译:任务组186(TG-186)的职责是为采用近距离放射治疗(BT)剂量计算的基于模型的剂量计算算法(MBDCA)的早期采用者提供指导,以确保实践的统一性。与外部束放射疗法相反,异质性校正算法直到最近才可用于BT社区。然而,BT剂量的计算精度高度依赖于散射条件和相对于水的光电效应截面。在特定情况下,当前的水性BT剂量计算形式主义(TG-43)与MBDCA之间的差异可能导致计算的剂量差异超过10倍。MBDCA提出了当前指导文件未解决的三个主要问题:( 1)MBDCA计算出的剂量对剂量规格介质敏感,导致在均质水几何形状(TG-43)中计算出的水剂量,在异质介质中计算出的局部剂量与中间情景之间的能量相关差异计算出的剂量是非均质介质中少量水的剂量。 (2)MBDCA剂量对逐个体素相互作用的横截面敏感。常规的单能CT或ICRUICRP组织组成汇编都没有为将交互截面分配给每个体素的任务提供有用的指导。 (3)由于每个患者-来源-施药者组合都是唯一的,因此为每种可能的组合提供参考数据以基准MBDCA是不切实际的策略。因此,需要新的调试过程。 TG-186通过文献综述详细解决了上述问题,并根据当前的知识水平提出了明确的建议。基于TG-43的剂量处方和剂量计算仍然有效,并在可用时并行执行MBDCA剂量报告。在使用MBDCA时,建议应在异质介质中进行辐射传输,并且至少应报告对局部介质的剂量以及TG-43计算出的剂量。逐个体素横截面的分配是一个特殊的挑战。电子密度信息很容易从CT成像中提取,但不能用于区分具有相同密度的不同材料。因此,建议使用多种标准化材料来保持各个机构之间的一致性。敏感性分析表明,与TG-43相比,此建议提供了更高的准确性。 MBDCA调试将与当前基于TG-43的系统共享共同点,但除此之外,还将有特定于算法的任务。建议进行两个级别的调试:再现TG-43剂量参数和测试MBDCA的高级功能。为了验证异质性和散布条件,MBDCA应该模仿参考虚拟几何图形的3D剂量分布。讨论了BT剂量处方和MBDCA限制的潜在变化。当完全实施MBDCA所需的数据不足时,会提出临时建议并确定潜在的研究领域。 TG-186指南的应用应在从TG-43过渡到MBDCA方法时保持实践的统一性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号